146 related articles for article (PubMed ID: 22112692)
1. Polycomb genes and cancer: time for clinical application?
Crea F; Paolicchi E; Marquez VE; Danesi R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):184-93. PubMed ID: 22112692
[TBL] [Abstract][Full Text] [Related]
2. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
Momparler RL; Côté S
Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
[TBL] [Abstract][Full Text] [Related]
3. 3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
Mayr C; Wagner A; Stoecklinger A; Jakab M; Illig R; Berr F; Pichler M; Di Fazio P; Ocker M; Neureiter D; Kiesslich T
Anticancer Res; 2015 Sep; 35(9):4697-705. PubMed ID: 26254359
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Crea F; Hurt EM; Mathews LA; Cabarcas SM; Sun L; Marquez VE; Danesi R; Farrar WL
Mol Cancer; 2011 Apr; 10():40. PubMed ID: 21501485
[TBL] [Abstract][Full Text] [Related]
5. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
6. The role of polycomb repressive complexes in biliary tract cancer.
Mayr C; Neureiter D; Wagner A; Pichler M; Kiesslich T
Expert Opin Ther Targets; 2015 Mar; 19(3):363-75. PubMed ID: 25424424
[TBL] [Abstract][Full Text] [Related]
7. 3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line.
Hatta M; Naganuma K; Kato K; Yamazaki J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):269-73. PubMed ID: 26505792
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.
Clermont PL; Fornaro L; Crea F
Epigenomics; 2017 Oct; 9(10):1329-1335. PubMed ID: 28875726
[TBL] [Abstract][Full Text] [Related]
9. Histone modifications, stem cells and prostate cancer.
Crea F; Clermont PL; Mai A; Helgason CD
Curr Pharm Des; 2014; 20(11):1687-97. PubMed ID: 23888964
[TBL] [Abstract][Full Text] [Related]
10. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
12. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells.
Aoki R; Chiba T; Miyagi S; Negishi M; Konuma T; Taniguchi H; Ogawa M; Yokosuka O; Iwama A
J Hepatol; 2010 Jun; 52(6):854-63. PubMed ID: 20395008
[TBL] [Abstract][Full Text] [Related]
13. MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.
Rajabi H; Hiraki M; Kufe D
Oncogene; 2018 Apr; 37(16):2079-2088. PubMed ID: 29379165
[TBL] [Abstract][Full Text] [Related]
14. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis.
Crea F; Fornaro L; Bocci G; Sun L; Farrar WL; Falcone A; Danesi R
Cancer Metastasis Rev; 2012 Dec; 31(3-4):753-61. PubMed ID: 22711031
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.
Kaito S; Iwama A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374737
[TBL] [Abstract][Full Text] [Related]
16. The Role of Polycomb Group Protein BMI1 in DNA Repair and Genomic Stability.
Fitieh A; Locke AJ; Motamedi M; Ismail IH
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804165
[TBL] [Abstract][Full Text] [Related]
17. 3-Deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells.
Shen L; Cui J; Pang YX; Ma YH; Liu PS
Asian Pac J Cancer Prev; 2013; 14(5):2915-8. PubMed ID: 23803053
[TBL] [Abstract][Full Text] [Related]
18. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
Zoabi M; Sadeh R; de Bie P; Marquez VE; Ciechanover A
Biochem Biophys Res Commun; 2011 May; 408(3):393-8. PubMed ID: 21513699
[TBL] [Abstract][Full Text] [Related]
19. Aberrations of EZH2 in cancer.
Chase A; Cross NC
Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
[TBL] [Abstract][Full Text] [Related]
20. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
